Calyx Bio-Ventures (CYX.H) Stock Statistics & Valuation Metrics
Total Valuation
Calyx Bio-Ventures has a market cap or net worth of CAD 947.82K. The enterprise value is ―.
- Market Cap
- CAD 947.82K
- Enterprise Value
- ―
Share Statistics
Calyx Bio-Ventures has 94,781,654 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 94,781,654
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Calyx Bio-Ventures’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
- Return on Equity (ROE)
- ―
- Return on Assets (ROA)
- ―
- Return on Invested Capital (ROIC)
- ―
- Return on Capital Employed (ROCE)
- ―
- Revenue Per Employee
- ―
- Profits Per Employee
- ―
- Employee Count
- 0
- Asset Turnover
- ―
- Inventory Turnover
- ―
Income Statement
In the last 12 months, Calyx Bio-Ventures had revenue of ― and earned -526.99K in profits. Earnings per share was ―.
- Revenue
- ―
- Gross Profit
- ―
- Operating Income
- -568.28K
- Pretax Income
- ―
- Net Income
- -526.99K
- EBITDA
- -513.60K
- Earnings Per Share (EPS)
- ―
Stock Price Statistics
- Beta
- ―
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Balance Sheet
Calyx Bio-Ventures has ― in cash and marketable securities with CAD 0.00 in debt, giving a net cash position of ― billion.
- Cash & Marketable Securities
- ―
- Total Debt
- CAD 0.00
- Net Cash
- ―
- Net Cash Per Share
- ―
- Tangible Book Value Per Share
- ―
Analyst Forecast
The average price target for Calyx Bio-Ventures is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―